Bevacizumab Treatment and Retinal Vessel Monitoring

Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy

Bevacizumab might influence the dynamic vessel function after being administered intravenously.

By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.

Inclusion Criteria:

• patients who wish and need bevacizumab treatment for underlying disease

Exclusion Criteria:

• previous bevacizumab treatment
• known eye disease, eye surgery or eye trauma in history
• myopia >-2.0 dpt
• hyperopia > +2.0 dpt.
• relevant media opacity of the lens
• acute heart disease, ischemic insult, proven coronary heart disease
• cardiac arrhythmia or vessel anomalies
• seizure disorder or episode in history
• migraine
• treatment with corticosteroids within 4 weeks before study inclusion
• intake of vasoactive drugs like AT-1 or glitazone
• pregnancy